



Press release |

A WORLDWIDE WAVE OF SUCCESS FOR THE IBA RHODOTRON®

Embargo up until 5.40 p.m. (Belgian time) – 7 January 2008

Louvain-la-Neuve, Belgium, 7 January 2008 – IBA (Ion Beam Applications S.A.: Reuters IBAB.BR and Bloomberg IBAB.BB) announces today that it has received four orders over the last few weeks for Rhodotron® to be used in the medical device sterilization market, worth an overall total of 10 to 15 million euros.

The four Rhodotron® will be delivered in 2008 en 2009:

- to one of the major producers of sterile medical devices in Malaysia,
- to Mediscan in Austria. This will be the company's second Rhodotron® and it will replace a linear accelerator, former to IBA's own unique technology. Mediscan had installed this linear accelerator fifteen or so years ago and then acquired a first Rhodotron® from IBA in 1998. The replacement of the linear accelerator confirms the excellence and superiority of IBA's Rhodotron® technology for the medical device sterilization market,
- to Univap in Brazil, for sterilization purposes, mainly involving medical devices and research and development,
- to one of the major producers of sterile medical devices in Japan.

The Rhodotron® is an electron beam particle accelerator which is designed mainly for use in industry. Amongst other things, it allows particularly effective sterilization of single-use medical products, the pasteurization of food, the improvement of both polymers and numerous other materials. IBA's electron beam particle accelerators account for approximately 80% of the installed power worldwide.

"These four orders, which are in addition to a sale made to BGS in Germany early 2007 and other current projects, show the increasing interest being shown in IBA's unique Rhodotron® type high energy and high power accelerator technology in industrial circles", commented Pierre Mottet, Chief Executive Officer of IBA. "The sterilization method for medical instruments using the Rhodotron® is becoming increasingly popular due to its productivity, speed, flexibility and simplicity", Mr Mottet added.

Press release |

ABOUT IBA

IBA delivers solutions of exceptional precision in the fields of cancer diagnosis and therapy. The company also provides sterilization and ionization solutions to improve the hygiene and safety of everyday life. IBA is listed on the pan-European stock exchange EURONEXT and belongs to the BelMid index.

Website: <http://www.iba-worldwide.com>.

Contact

IBA

Paul-Emmanuel Goethals
Director, Corporate Business Development
& Investor Relations
Tel.: +32 10 47 58 16
paul-emmanuel.goethals@iba-group.com

The IBA Rhodotron®

